Treatment of Patients With Takayasu Arteritis Complicated With Pulmonary Artery Involvement

Launched by CHINESE PULMONARY VASCULAR DISEASE RESEARCH GROUP · May 19, 2022

Keywords

ClinConnect Summary

This clinical trial is looking at how effective certain treatments are for patients with Takayasu arteritis, a type of inflammation of the arteries that can affect the pulmonary arteries, which supply blood to the lungs. The trial will assess the impact of medical treatments and a specific procedure called percutaneous transluminal pulmonary angioplasty, which helps open up narrowed blood vessels. Additionally, researchers will investigate a new imaging method, known as FAPI, to see if it can help predict how active the disease is and how well the treatments are working.

To participate in this trial, patients need to have a diagnosis of Takayasu arteritis that involves the pulmonary arteries. However, those with other specific conditions related to the pulmonary arteries will not be eligible. If you or someone you know is considering joining this trial, you can expect to receive close monitoring and care as part of the study. The trial is currently recruiting participants of all ages and genders, so it's an opportunity for anyone affected by this condition to contribute to important research that may improve treatment options.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • patients diagnosed with Takayasu arteries with pulmonary arteries involvement
• Exclusion Criteria:
• • Patients had pulmonary artery stenosis arising from CTEPH, fibrosing mediastinitis and congenital pulmonary artery stenosis